title: Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
authors.forename: Murielle
authors.initials: M
authors.lastname: Roussel
authors.forename: Sajitha
authors.initials: S
authors.lastname: Sachchithanantham
authors.forename: Simon D J
authors.initials: SD
authors.lastname: Gibbs
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Venner
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Pinney
authors.forename: Julian D
authors.initials: JD
authors.lastname: Gillmore
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Lachmann
authors.forename: Philip N
authors.initials: PN
authors.lastname: Hawkins
authors.forename: Ashutosh D
authors.initials: AD
authors.lastname: Wechalekar
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007072:Immunoglobulin D / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D007072:Immunoglobulin D; D011719:Pyrazines; D013792:Thalidomide; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide
keywords: IgD amyloidosis; immunoglobulin D; light chain amyloidosis; rare amyloidosis; systemic AL amyloidosis